A call for guidance on the treatment of patients taking disease-modifying anti-rheumatic drugs (DMARDs)

Disease-modifying anti-rheumatic drug (DMARD) use in patients presenting to oral and maxillofacial departments should be duly noted. DMARDs lead to immunosuppression and have the potential to suppress anti-tumour immunity.1 DMARD is an encompassing term for both conventional DMARDs (for example, methotrexate, hydroxychloroquine, sulfasalazine, and azathioprine), biologic DMARDs (for example, adalimumab and rituximab), and targeted synthetic DMARDs (for example, filgotinib). DMARDs are increasingly used for cancer and autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn ’s disease.
Source: The British Journal of Oral and Maxillofacial Surgery - Category: ENT & OMF Authors: Tags: Letter to the Editor Source Type: research